May 17, 2020

Mayo Clinic just launched an alternative to BMI

Mayo Clinic
Body Volume Indicator
Body Mass Index
Select Research
2 min
Mayo Clinic just launched an alternative to BMI
Mayo Clinic has devised a new way to measure weight that could very well challenge the decades-old Body Mass Index (BMI) method currently the mainstay o...

Mayo Clinic has devised a new way to measure weight that could very well challenge the decades-old Body Mass Index (BMI) method currently the mainstay of the world’s medical profession.

Known as the Body Volume Indicator (BVI), the new technique has been designed to offer a more precise estimate of weight distribution and fat around organs. Simply put, the new method works by dividing total volume with abdominal volume. Select Research, a company specialised in providing 3D measurements, has developed an iPad app, BVI Pro that can calculate a person's BVI with a simple scan.

According to fastcompany, Mayo Clinic will be the first hospital to use this new measurement, and will be disseminating it to members of its medical, clinical, and fitness communities, but it hopes that this will eventually become a standard for measuring body mass by 2020, supplementing the BMI.

For those who don’t know, Mayo Clinic is a not-for-profit medical practice incorporating its medical research group based in Minnesota USA. The company employs over 4,500 physicians and scientists, alongside almost 60,000 allied health staff.

The practice specializes in treating difficult cases through tertiary care. It spends over $660 million a year on research BMI has been used by the medical community for a very long time and was developed in order to identify whether someone is the correct weight. The value is calculated by dividing weight by the square of the patient’s height.

However, anybody that has used it with any consistency has learned that its reputation for being too broad a measure to accurately identify optimal weight or body fat content is true. 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article